Phase 2 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a heart condition called hypertrophic cardiomyopathy (a thickened heart muscle) and have already taken part in a previous study related to a drug called HRS-1893.
- If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before starting the trial and must not be breastfeeding during the study.
- Women who could become pregnant and men whose partners could become pregnant must agree to use contraception and not donate eggs or sperm from the time they sign the consent form until 3 months after the last dose of the trial drug.
- You understand what the trial involves, are willing to take part, and are able to sign a consent form.
Who may not be able to join:
- You have a history of blocked heart arteries (more than 70% blockage in one or more arteries) or have previously had a heart attack.
- In the 4 weeks before screening, you have taken heart medications that reduce the strength of your heartbeat, other than specific allowed ones (disopyramide, beta-blockers, verapamil, or diltiazem).
- You have had a fainting episode or a serious, prolonged rapid heartbeat rhythm problem in the 6 months before screening.
- The trial doctor believes, for any reason, that joining this trial would not be safe or appropriate for you — for example, due to a physical or mental health condition, or concerns about your ability to follow the trial requirements (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-0518-82342973
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of adverse events (AEs).; Incidence of left ventricular ejection fraction (LVEF) <50%.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.